University of Leicester
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study..pdf (700.85 kB)

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study

Download (700.85 kB)
journal contribution
posted on 2015-08-04, 09:07 authored by M. Jamal-Hanjani, A. Hackshaw, Y. Ngai, Jacqueline Shaw, C. Dive, S. Quezada, G. Middleton, E. de Bruin, John Le Quesne, S. Shafi, M. Falzon, S. Horswell, F. Blackhall, I. Khan, S. Janes, M. Nicolson, D. Lawrence, M. Forster, Dean Fennell, SM Lee, J. Lester, K. Kerr, Salli Muller, N. Iles, S. Smith, N. Murugaesu, R. Mitter, M. Salm, A. Stuart, N. Matthews, H. Adams, T. Ahmad, R. Attanoos, Jonathan Bennett, N. J. Birkbak, R. Booton, G. Brady, K. Buchan, A. Capitano, M. Chetty, M. Cobbold, P. Crosbie, H. Davies, A. Denison, M. Djearman, J. Goldman, T. Haswell, L. Joseph, M. Kornaszewska, M. Krebs, G. Langman, M. MacKenzie, J. Millar, Bruno Morgan, B. Naidu, D. Nonaka, K. Peggs, Catrin Pritchard, H. Remmen, A. Rowan, R. Shah, E. Smith, Y. Summers, M. Taylor, S. Veeriah, David Waller, B. Wilcox, M. Wilcox, I. Woolhouse, N. McGranahan, C. Swanton
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.



PLoS Biol, 2014, 12 (7), e1001906

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine


  • VoR (Version of Record)

Published in

PLoS Biol


Public Library of Science



Copyright date


Available date


Publisher version